Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01270802 · ClinicalTrials.gov registry record · Phase 4
Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients
A Phase 4 study, sponsored by Indiana University.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT01270802 is a Phase 4 study that has completed, run by Indiana University. The registered enrollment target is 30 participants.
The verdict
NCT01270802, a Phase 4 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
Efavirenz, a commonly used HIV medication, may cause worsening vascular function and bone problems. The purpose of this study is to determine if switching efavirenz to raltegravir, a newer HIV medication, will improve vascular function and tests of bone health.
Interventions
- DRUG Raltegravir
- DRUG Tenofovir/emtricitabine
- DRUG Tenofovir/emtricitabine/efavirenz
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2011-04 |
| Est. Completion | 2013-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01270802
The ClinicalTrials.gov registry entry for NCT01270802 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Raltegravir is the first listed.
NCT01270802 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01270802 about?
NCT01270802 is a clinical study titled "Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients". Efavirenz, a commonly used HIV medication, may cause worsening vascular function and bone problems. The purpose of this study is to determine if switching efavirenz to raltegravir, a newer HIV medication, will improve vascular function and tests of bone health.
What is the current status of trial NCT01270802?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2011-04. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01270802?
The interventions under investigation include: Raltegravir (DRUG), Tenofovir/emtricitabine (DRUG), Tenofovir/emtricitabine/efavirenz (DRUG).
Who is sponsoring clinical trial NCT01270802?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.